Proteomic biomarkers for autoimmune disease.
Autoimmune diseases affect 3% of the world population, yet the diagnosis and classification of autoimmune diseases remain based on clinical examination combined with traditional laboratory tests and imaging studies. The development of genomic and proteomic technologies provides an unprecedented ability to identify novel biosignatures to diagnose, classify, and guide therapeutic decision making in patients with autoimmune disease. In this article, we review recent advances in proteomics technologies and their application to autoimmune disease.
Hueber
Wolfgang
W
Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, CA, USA. whueber@stanford.edu
Robinson
William H
WH
D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000175:diagnosis*; D015415:Biomarkers / Q000097:blood*; D006801:Humans; D040081:Protein Array Analysis; D040901:Proteomics
D001323:Autoantibodies; D015415:Biomarkers